Japan's Takeda To Partner With Envoy Of U.S. On Schizophrenia Drugs
This article was originally published in PharmAsia News
Executive SummaryJapan's Takeda Pharmaceutical and U.S. drug maker Envoy Therapeutics have signed an agreement to collaborate on developing schizophrenia drugs
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.